Study Confirms Benefit of Inhaled Corticosteroids for COPD
While recent studies have shed some doubt about the benefits of using inhaled corticosteroids as a top-line treatment for COPD, a recent review of studies confirms they do, indeed, benefit COPD patients. Inhaled corticosteroids (ICS) are medicines that work to reduce inflammation in COPD lungs; thus, making airways less sensitive to COPD triggers. Common inhalers that deliver inhaled steroids to COPD lungs include Qvar, Advair, Symbicort, and Breo. Pulmicort may be delivered using a nebulizer. While typically considered top-line COPD medicines, various studies have linked inhaled corticosteroids with pneumonia. Other studies show they don’t even reduce COPD flare-ups. So this left many physicians wondering if the benefits were worth the risks.
A new study, however, reported at the 2015 American Thoracic Society Conference in Denver, shines the light back in the other corner, indicating that, yes indeed, ICS do benefit COPD patients. The study was a material analysis study, meaning that results from over 29 randomized trials and observational studies were analyzed.
According to RT Magazine, “ICS for COPD Decrease Mortality Risk for Pneumonia, Other Causes,” six of the randomized trials showed ICS did not increase the risk of pneumonia, and seven of the observational studies actually showed a decrease in the risk of pneumonia.
Overall, the review shows that ICS may still increase the risk for getting pneumonia among the COPD population. At the same time, however (and this is the good news), ICS lowers the risk of COPD patients dying from pneumonia or any other cause.
Basically, even though ICS may increase your risk for acquiring pneumonia, they make your COPD flare-ups less severe; they make your lungs stronger and better capable of dealing with the flare-ups caused by any asthma trigger.
With any medicine used for any disease condition, it’s always important to weigh the benefits against any potential risks. One potential risk of ICS may be the risk of getting pneumonia. A potential benefit is that they may help you live better – and longer – with COPD. Speak with your doctor if you are considering these medications.
John Bottrell is a registered Respiratory Therapist. He wrote for HealthCentral as a health professional for Asthma and Chronic Obstructive Pulmonary Disease (COPD).